Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Desarrollo de modelos in vitro e in vivo para descubrimiento de nuevos medicamentos, con especial atención en imágenes de bioluminiscencia y fluorescencia

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOEE20151218001
Publicado:
21/12/2015
Caducidad:
21/12/2016
Resumen:
Una spin-off estonia con experiencia en biología molecular y ensayos con modelos animales lleva a cabo procesos de diseño, clonación y producción de vectores lentivirales para expresar genes de interés y generar líneas celulares estables. La empresa utiliza nuevos marcadores bioluminiscentes y fluorescentes en imagen multicolor de todo el cuerpo de modelos de enfermedad animal. El principal campo de aplicación es la investigación preclínica del cáncer, neurodegeneración y micriobiota. La empresa busca socios con el fin de establecer acuerdos de servicio y participar en proyectos de investigación.

Details

Tittle:
Development of preclinical in vitro and in vivo models aiding novel drug discovery and with special focus on bioluminescence and fluorescence imaging
Summary:
Estonian spin-off company with molecular cell biology and animal model testing background performs lentiviral vector design, cloning and production to express genes of interest and to generate stable cell lines. They use novel bioluminescent and fluorescent markers in whole-body multicolour imaging of animal disease models. Preclinical research in cancer, neurodegeneration and microbiota is the main application field. They are looking for service agreements and collaborative research projects.
Description:
The company is a small spin-off company from an Estonian technology-oriented university and their broad field of activity is bio-medical research, more precisely: cancer research, monitoring of disease states in deep tissues and its response to therapy.

In bio-medical research, development of novel therapeutics against cancer and neurodegenerative diseases is emerging rapidly. However, the most popular preclinical cancer models, subcutaneous xenografts in nude mice, are known to have low predictive value for clinical efficacy of novel drugs, neither do they recapitulate metastasis models. By optical whole-body imaging of animal models, the company offers possibility to monitor disease states in deep tissues and its response to therapy. They offer services to produce disease model of interest by expressing a protein or RNA in a chosen tumor cell line, and to perform efficacy tests of novel drug candidates in vivo. In order to develop more accurate disease models, they clone and test novel markers bio-luminescent and fluorescent. The company also works with microbiome (symbiotic bacteria living in human gut) that has emerged as a major health issue, having effect on cancer, obesity, metabolic and autoimmune diseases.

The spin-off company seeks for two kinds of partners: partners for collaborative research projects (for developing the area further, new methods, new technical tools) and service agreements (for providing previously mentioned services to international partners).

Under the first, they are looking for partners who are willing to contribute to the development of novel drug projects, disease models and fluorescent markers. Since the company is also involved in supervising PhD and graduate student projects, they can host secondments that are relevant for having a more competent research project staff. Under the second, they are interested in clients to whom they can provide custom novel drug development projects that involve DNA cloning, cell culture and animal disease model services.
Advantages and Innovations:
Viral vectors are tools for genetic manipulation of cells and organisms. Multicolour imaging opens new possibilities in novel drug development, enabling to generate biologically more relevant disease models that can be also non-invasive monitored during studies. For this purpose, the company has established tumor cell lines that are able to express various fluorescent proteins and luciferases.

The main advantage is that every step, from DNA vector cloning to cell culture and animal experimentation, is carried out in one lab. This is more a process innovation that enables the company to control and stabilize the experiment process, different steps and actors in a more efficient and effective way.
Stage of Development:
Available for demonstration
IPs:
Secret Know-how,Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Protection has been applied for US patent

Partner sought

Type and Role of Partner Sought:
The company is seeking for two types of partnerships.

First, looking for research collaboration agreements with academia or industry to work on and validate imaging technologies in novel drug development (disease models and fluorescent markers). Since the company is involved in supervising PhD and graduate student projects, they can host secondments that are required in Marie-Sklodowska-Curie actions, for example.

Secondly, they are interested in service agreements and seek for clients to whom they can provide custom novel drug development projects. Their competence involves DNA cloning, lentiviral vectors, cell culture methods including stable cell generation and animal disease model services, focusing to xenograft studies (both subcutaneous and orthotopic). They also provide custom experimental design and full statistical analysis of results.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Russian

Keywords

Technology Keywords:
08001002 Aditivos / ingredientes alimentarios / alimentos funcionales
06001003 Citología, cancerología, oncología
06002005 Ingeniería genética
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos